Immune Thrombocytopenia
Conditions
Keywords
corticosteroid-resistant or relapsed ITP, eltrombopag, recombinant human thrombopoietin (rhTPO)
Brief summary
This is a prospective, single-arm study to investigate the efficacy and safety of the combination of fixed low-dose eltrombopag plus recombinant human thrombopoietin (rhTPO) as treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients during the COVID-19 pandemic.
Detailed description
Eltrombopag, a small molecule agonist of thrombopoietin receptor (TPO-RA), was recommended as the subsequent treatment for ITP patients, which also already showed robust efficacy.Recombinant human thrombopoietin (rhTPO) is a full-length glycosylated-TPO produced by Chinese hamster ovary cells, which showed its effectiveness in ITP in a variety of studies. Both eltrombopag and rhTPO demonstrated good safety in ITP patients. Because of their non-immunosuppressive nature, both of them serve as a reasonable choice during the global COVID-19 pandemic. Since they increase the number of platelets through different mechanisms, and previous studies demonstrated that they might exert synergic effect. The investigators hypothesized that the combination of these two agents could be a promising option for treatment of corticosteroid-resistant or relapsed ITP patients.
Interventions
DRUGEltrombopag
Fixed dose of eltrombopag oral 25mg daily
DRUGrhTPO
Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
Sponsors
Peking University People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Clinically confirmed corticosteroid-resistant or relapsed immune thrombocytopenic purpura (ITP) 2. Subject has signed and provided written informed consent. 3. Fertile patients must use effective contraception during treatment and observational period 4. Negative pregnancy test
Exclusion criteria
1. Have an impaired renal function as indicated by a serum creatinine level \> 2.0 mg/dL 2. Have an inadequate liver function as indicated by a total bilirubin level \> 2.0 mg/dL and/or an aspartate aminotransaminase or alanine aminotransferase level \> 3×upper limit of normal 3. Have a New York Heart Classification III or IV heart disease 4. Have a history of severe psychiatric disorder or are unable to comply with study and follow-up procedures 5. Have active hepatitis B or hepatitis C infection 6. Have a HIV infection 7. Have active infection requiring antibiotic therapy within 7 days prior to study entry 8. Are pregnant or lactating women, or plan to become pregnant or impregnated within 12 months of receiving study drug 9. Previous splenectomy 10. Had previous or concomitant malignant disease 11. Not willing to participate in the study. 12. Expected survival of \< 2 years 13. Intolerant to murine antibodies 14. Immunosuppressive treatment within the last 2 weeks 15. Connective tissue disease 16. Autoimmune hemolytic anemia 17. Patients currently involved in another clinical trial with evaluation of drug treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete response | 6 weeks | A complete response (CR) was defined as a sustained (≥ 3 months) platelet count ≥ 100×10\^9/L. |
| Response | 6 weeks | A response (R) was defined as a sustained (≥ 3 months) platelet count ≥ 30×10\^9/L without recurrence of thrombocytopenia. |
| No response | 6 weeks | No response (NR) was defined as platelet count \< 30 × 10\^9/L or a less than two fold increase in platelet count from baseline or the presence of bleeding. Platelet count must be measured on two occasions more than a day apart. |
| Relapses | 6 weeks | A relapses was defined as platelet count falls below 30×10\^9/L or bleeding accrues after achieving R or CR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatments associated adverse events | 6 weeks | All patients were assessed for safety every week during the first 8 weeks of treatment, and at 2-week intervals thereafter. Adverse events were scaled according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
| Early response | 7 days | Early response was defined as the attainment of a platelet count ≥ 30 × 10⁹ and at least a doubling of baseline platelet count at 1 week. |
| Reduction in bleeding symptoms | 6 weeks | Changes of bleeding after treatment. Bleeding was defined in accordance with the WHO bleeding scale (0, no bleeding; 1, petechiae; 2, mild blood loss; 3, gross blood loss; and 4, debilitating blood loss). |
| Initial response | 1 month | Initial treatment was defined as the attainment of a platelet count ≥ 30 × 10⁹ and at least a doubling of baseline platelet count at 1 month. |
| TOR (time to response) | 6 weeks | The time to achieve platelet count ≥ 30×10\^9/L and at least 2-fold increase of the baseline count and absence of bleeding since start of treatment. |
| DOR (duration of response) | 6 weeks | The duration of achieve platelet count ≥ 30×10\^9/L and at least 2-fold increase of the baseline count and absence of bleeding since start of treatment. |
Countries
China
Contacts
Primary ContactXiaohui Zhang, MD
Backup ContactXuelin Dou, MD
Outcome results
None listed